Are we there yet? Prolonged MAPK inhibition in BRAFV600-mutant melanoma

威罗菲尼 黑色素瘤 MEK抑制剂 医学 曲美替尼 MAPK/ERK通路 癌症研究 内科学 肿瘤科 达布拉芬尼 激酶 转移性黑色素瘤 生物 细胞生物学
作者
Nikhil I. Khushalani,Vernon K. Sondak
出处
期刊:Lancet Oncology [Elsevier]
卷期号:17 (9): 1178-1179 被引量:6
标识
DOI:10.1016/s1470-2045(16)30368-0
摘要

The years 2011–16 represent a watershed era in melanoma history. 1 Merlino G Herlyn M Fisher DE et al. The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res. 2016; 29: 404-416 Crossref PubMed Scopus (69) Google Scholar This period has seen the approval of several molecularly targeted or immunotherapy drugs that meaningfully improve outcomes for patients with unresectable or metastatic melanoma. Targeting the MAP kinase (MAPK) pathway through combined BRAF and MEK inhibition has been very successful, yet the eventual development of resistance through reactivation of MAPK signalling is nearly inevitable. 2 Paraiso KH Fedorenko IV Cantini LP et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010; 102: 1724-1730 Crossref PubMed Scopus (253) Google Scholar In The Lancet Oncology, Paolo Ascierto and colleagues report the extended follow-up results of the coBRIM phase 3 trial evaluating the addition of the MEK inhibitor cobimetinib to the BRAF inhibitor vemurafenib in patients with previously untreated BRAFV600-mutant metastatic melanoma. 3 Ascierto PA McArthur GA Dréno B et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016; (published online July 29.)http://dx.doi.org/10.1016/S1470-2045(16)30122-X Google Scholar With longer follow-up (median 14·2 months [IQR 8·5–17·3]) than the initial report, the results confirm a significant improvement in progression-free survival for vemurafenib plus cobimetinib compared with vemurafenib plus placebo (12·3 months vs 7·2 months; HR 0·58 [95% CI 0·46–0·72], p<0·0001), which also translated into longer overall survival in the combination therapy group (22·3 months vs 17·4 months; HR 0·70 [95% CI 0·55–0·90], p=0·005). Exploratory biomarker analyses did not show an association with survival, and we remain woefully unable to predict for individual patients with BRAFV600-mutant melanoma what the magnitude and duration of response to targeted therapy will be. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialThese data confirm the clinical benefit of cobimetinib combined with vemurafenib and support the use of the combination as a standard first-line approach to improve survival in patients with advanced BRAFV600-mutant melanoma. Full-Text PDF
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
3秒前
han发布了新的文献求助10
3秒前
3秒前
4秒前
小博士328发布了新的文献求助10
5秒前
5秒前
传奇3应助水博士采纳,获得10
8秒前
ai发布了新的文献求助10
8秒前
10秒前
11秒前
我爱夏天完成签到,获得积分10
11秒前
Murray应助火星上的亦寒采纳,获得10
12秒前
13秒前
坐以待币完成签到,获得积分10
13秒前
13秒前
ai完成签到,获得积分10
15秒前
坐以待币发布了新的文献求助10
17秒前
会飞的猪发布了新的文献求助10
17秒前
xiaoou发布了新的文献求助10
17秒前
赘婿应助科研通管家采纳,获得10
17秒前
17秒前
iNk应助科研通管家采纳,获得10
17秒前
tomorrow505应助科研通管家采纳,获得10
17秒前
T012发布了新的文献求助10
17秒前
传奇3应助科研通管家采纳,获得10
17秒前
不来应助科研通管家采纳,获得10
18秒前
cocolu应助科研通管家采纳,获得10
18秒前
Jasper应助大翟采纳,获得10
18秒前
顾矜应助科研通管家采纳,获得10
18秒前
情怀应助科研通管家采纳,获得10
18秒前
我是老大应助科研通管家采纳,获得10
18秒前
田様应助猫雷采纳,获得10
19秒前
FashionBoy应助陈伊森采纳,获得10
20秒前
20秒前
21秒前
温暖的秋荷完成签到,获得积分10
21秒前
东方欲晓应助顺心的舞蹈采纳,获得10
22秒前
小璐sunny发布了新的文献求助10
22秒前
22秒前
高分求助中
Solution Manual for Strategic Compensation A Human Resource Management Approach 1200
Natural History of Mantodea 螳螂的自然史 1000
Glucuronolactone Market Outlook Report: Industry Size, Competition, Trends and Growth Opportunities by Region, YoY Forecasts from 2024 to 2031 800
A Photographic Guide to Mantis of China 常见螳螂野外识别手册 800
Autoregulatory progressive resistance exercise: linear versus a velocity-based flexible model 500
The analysis and solution of partial differential equations 400
Spatial Political Economy: Uneven Development and the Production of Nature in Chile 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 细胞生物学 免疫学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3334609
求助须知:如何正确求助?哪些是违规求助? 2963868
关于积分的说明 8611689
捐赠科研通 2642793
什么是DOI,文献DOI怎么找? 1446965
科研通“疑难数据库(出版商)”最低求助积分说明 670499
邀请新用户注册赠送积分活动 658693